Barinthus Biotherapeutics plc (BRNS)
NASDAQ: BRNS · IEX Real-Time Price · USD
2.380
+0.030 (1.28%)
At close: Mar 28, 2024, 3:58 PM
2.300
-0.080 (-3.36%)
After-hours: Mar 28, 2024, 4:06 PM EDT
Barinthus Biotherapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for BRNS stock has a target of 8.00, which predicts an increase of 236.13% from the current stock price of 2.38.
Analyst Consensus: Strong Buy
Analyst Ratings
According to 1 stock analyst, the rating for BRNS is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Jan '24 | Feb '24 | Mar '24 |
---|---|---|---|
Strong Buy | 1 | 1 | 1 |
Buy | 0 | 0 | 0 |
Hold | 0 | 0 | 0 |
Sell | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 |
Total | 1 | 1 | 1 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 → $8 | Strong Buy | Maintains | $15 → $8 | +236.13% | Mar 21, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +530.25% | Nov 28, 2023 |
Financial Forecast
Revenue This Year
350.20K
from 802.00K
Decreased by -56.33%
Revenue Next Year
408.00K
from 350.20K
Increased by 16.51%
EPS This Year
-2.28
from -1.91
EPS Next Year
-2.28
from -2.28
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|
High | 2.1M | 2.1M | 1.1M | n/a |
Avg | 350,197 | 408,000 | 510,000 | n/a |
Low | n/a | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|
High | 161.8% | 499.7% | 157.4% | - |
Avg | -56.3% | 16.5% | 25.0% | - |
Low | - | - | - | - |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|
High | -1.16 | -1.01 | -1.84 | -3.17 |
Avg | -2.28 | -2.28 | -2.14 | -3.08 |
Low | -2.91 | -3.24 | -2.39 | -2.96 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|
High | - | - | - | - |
Avg | - | - | - | - |
Low | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.